James Garner Purchases 65,000 Shares of Kazia Therapeutics Ltd (ASX:KZA) Stock

Share on StockTwits

Kazia Therapeutics Ltd (ASX:KZA) insider James Garner bought 65,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was bought at an average cost of A$0.33 ($0.23) per share, with a total value of A$21,515.00 ($15,258.87).

KZA stock opened at A$0.64 ($0.45) on Thursday. The firm has a 50-day moving average price of A$0.51 and a 200-day moving average price of A$0.44. Kazia Therapeutics Ltd has a 12 month low of A$0.32 ($0.23) and a 12 month high of A$0.80 ($0.57). The stock has a market capitalization of $39.79 million and a P/E ratio of -3.58.

About Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.

Further Reading: What is a Real Estate Investment Trust (REIT)?

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GRUPO AVAL ACCI/S  & Bank of Montreal  Critical Analysis
GRUPO AVAL ACCI/S & Bank of Montreal Critical Analysis
Analyzing Trip.com Group  & Its Rivals
Analyzing Trip.com Group & Its Rivals
Analyzing Hilton Hotels  and Wyndham Destinations
Analyzing Hilton Hotels and Wyndham Destinations
Head-To-Head Review: EXACT Sciences  and National Research
Head-To-Head Review: EXACT Sciences and National Research
Reviewing Jacobs Engineering  and KBR
Reviewing Jacobs Engineering and KBR
Orestone Mining  Trading 40% Higher
Orestone Mining Trading 40% Higher


© 2006-2020 Ticker Report